- Home
- SLVM vs INBX Comparison
SLVM vs INBX Comparison
Compare SLVM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLVM | INBX |
|---|---|---|
| Founded | 1898 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SLVM | INBX |
|---|---|---|
| Price | $39.39 | $92.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $54.00 | ★ $150.00 |
| AVG Volume (30 Days) | 311.8K | ★ 331.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,351,000,000.00 | $1,300,000.00 |
| Revenue This Year | $0.93 | N/A |
| Revenue Next Year | $1.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $35.53 | $20.55 |
| 52 Week High | $56.80 | $155.29 |
Technical Indicators
Market Signals| Indicator | SLVM | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 44.82 |
| Support Level | $38.74 | $85.94 |
| Resistance Level | $40.26 | $96.12 |
| Average True Range (ATR) | 1.33 | 7.44 |
| MACD | 0.04 | 0.79 |
| Stochastic Oscillator | 65.99 | 33.15 |
Price Performance
Historical ComparisonAbout SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.